TOPPAN Holdings Inc. (President & COO: Satoru Oyama, hereinafter TOPPAN Holdings) developed the medical information analysis and provision service "DATuM IDEA®" (pronounced: Day-tum Idea) in April 2022, based on electronic health record data, and is currently providing it mainly to pharmaceutical companies. Effective July 1, 2026, free-text data held by 55 medical facilities nationwide will be added. The number of target facilities for this data linkage will be the largest in Japan for text data held by certified operators under the Next Generation Medical Infrastructure Act (Note 1). The data to be added this time consists of anonymized text information recorded in the free-description fields of electronic health records and referral letters. Information such as doctors' treatment decisions, patient needs (chief complaints, etc.), changes in symptoms, occurrence of side effects, and reasons for drug changes/discontinuation will be extracted from the text data. By combining this with structured data with unified items and formats (disease names, drug names, drug dosages, laboratory test data, etc.), highly reliable and high-quality analysis is possible, linking not only objective treatment outcomes but also the reasons behind them. TOPPAN will continue to support the identification of medical needs and the creation of evidence aligned with the realities of medical practice in disease areas where there are significant medical needs but no established treatments, thereby contributing to the acceleration of drug discovery. Flow to Text Data Provision ■ Background In recent years, the importance of utilizing real-world data (Note 2) based on actual clinical practice has been increasing among pharmaceutical companies. Previously, objective numerical analysis using structured data with unified items and formats (disease names, drug names, drug dosages, laboratory test data, etc.) and medical receipt data (medical fee statements) was mainstream. However, as data utilizatio